Entasis Therapeutics to Present on ETX2514SUL at IDWeek 2018
Details of the presentation are as follows:
Oral Presentation: ETX2514/sulbactam
Session: Exploring the Antibiotic Pipeline 2018 Symposium
Date and Time:
Location: Room N Hall D
A Phase 3 clinical trial evaluating ETX2514SUL against carbapenem-resistant A. baumannii infections will begin in the first quarter of 2019.
ETX2514 is a potent and broad-spectrum inhibitor of class A, C, and D β-lactamases. ETX2514 restores the in vitro activity of multiple β-lactams against Gram-negative, multidrug-resistant (MDR) pathogens.
This press release includes certain disclosures which contain “forward-looking statements,” including, without limitation, statements regarding Entasis’ expectations regarding the commencement of trading of its shares on the
Source: Entasis Therapeutics Holdings Inc.